Five ways the wiki draws an idea
Dark teal glass on a light page, after the My-Pepts graphics. Every one below is live, drawn from the retatrutide page's own data, and each says in text what it shows.
Type 1
Steps
A short sequence that has a real order: reconstitution, how a trial is run, how a compound reaches a license. Cards arrive along a rail, once.
从粉末到测量好的样品
对任何冻干小瓶都是同样的四个步骤。仅指实验室操作,并非用于人体。
1. 阅读小瓶标签
标签给出小瓶中肽的质量,单位为毫克。这个数字是所有计算的起点。
2. 加入稀释剂
将量好的稀释剂沿玻璃壁缓慢加入。轻轻旋转;摇晃可能损伤肽。
3. 计算浓度
浓度等于质量除以体积:10 毫克溶于 2 毫升即为每毫升 5 毫克。
4. 量取样品
体积等于所需质量除以浓度。在 U-100 注射器上,1 毫升即 100 单位。
Type 2
Orbit
One thing and what it acts on: a molecule and its receptors, a blend and its parts. Lines flow outward; picking a node explains it.
一种分子,作用于什么
它结合的靶点,以及每个受体已知的作用。请选择一项。
GIP receptor. In vitro the molecule is more active here than at the other two receptors. In obese mice the discovery paper credits GIP and GLP-1 receptor activity with the reduction in calorie intake 6.
Type 3
Trial bars
Results by arm of a published trial, switched by outcome. Comparators are pink. A hidden table carries the same numbers for screen readers.
试验测量了什么
每个柱子代表已发表试验中的一个组别:分配到该剂量组的人群平均变化。请选择一项结局指标。
Change in body weight at 48 weeks
| Arm | Mean change |
|---|---|
| Placebo (comparator) | -2.1% |
| 1 mg | -8.7% |
| 4 mg | -17.1% |
| 8 mg | -22.8% |
| 12 mg | -24.2% |
Least-squares mean percentage change from baseline in the phase 2 obesity trial, 338 adults. The 4 mg and 8 mg figures pool two arms that differed only in starting dose.
粉色柱子为对照组。试验结果是受监测人群的平均值,并非对某个人的预测。
Type 4
Timeline ribbon
A compound's history, year by year, lighting in order along a line. Scrolls sideways on a phone.
从首次试验到今天
Retatrutide: 逐年展示。左右滚动可查看完整时间线。
- 2019
The phase 1b trial in type 2 diabetes begins enrolling in December, at four centers in the USA 5.
- 2021
The phase 2 obesity trial is registered and randomizes its first participants; the phase 2 diabetes trial begins 210.
- 2022
The discovery paper and the phase 1b results are published under the code LY3437943 56.
- 2023
The phase 2 results in obesity and in type 2 diabetes are published 12.
- 2024
The MASLD substudy is published; TRANSCEND-T2D-1 begins randomizing; a head-to-head trial against tirzepatide is registered 3412.
- 2025
A systematic review and meta-analysis pools four placebo-controlled trials 7.
- 2026
The TRANSCEND-T2D-1 results and the TRANSCEND-CKD design paper are published 49.
Type 5
Evidence ladder
Where a compound stands between cell studies and a licensed medicine, with what PubMed holds. It is on every compound page, stubs included.
它攀登到了哪一级
每种药物都要攀登同一架阶梯。大多数化合物从未到达顶端,其所处位置决定了其主张能有多大的依据。
- 已获许可的药物
监管机构已审查这些试验,并批准其用于特定用途。
- Phase 3: Retatrutide
大型随机试验,通常有数千人,与安慰剂或标准治疗对照。
- Phase 2
中等规模试验,在患有相应疾病的人群中测量剂量与效果的关系。
- Phase 1 and early human studies
首次在人体中进行的研究:安全性以及身体如何处理该物质。
- 细胞与动物
实验室及动物研究。动物实验的结果不等同于人体结果。
- 219
- PubMed 上的论文
- 133
- 其中以人为对象的研究
- 11
- 随机试验
- 136
- 综述
文献数量只说明发表了多少,并不说明结果如何。在 PubMed 上统计的数量: 2026-11-16
And in three dimensions
The bead chain
Every compound has its own chain, grown from its name: the wiki's picture of a peptide. On a wide screen it turns slowly in 3D and leans toward the pointer; on a phone, with reduced motion or without WebGL it is a still drawing.
Open this page on a wider screen to see it turn.